GMA106 / Gmax Biopharm, Sino Biopharm - LARVOL DELTA

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106 (clinicaltrials.gov) - P1 | N=73 | Completed | Sponsor: Gmax Biopharm Australia Pty Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

China Biopharma (01177.HK) phase IB/II clinical trial application for innovative drug GMA106 was accepted by CDE (jrj.com) - "China Biopharma (01177.HK) announced that the Category 1 innovative drug 'GMA106 (GIPR antagonist/GLP-1R agonist)' jointly developed by the group has been submitted to the Drug Evaluation Center of the China National Medical Products Administration. ('CDE') submitted and was accepted a Phase Ib/II clinical trial application for the treatment of adults with overweight and obesity....In China, GMA106 plans to further confirm the safety and tolerability of multiple doses at higher doses in overweight and obese people through a Phase Ib study."

New P1/2 trial • Metabolic Disorders • Obesity